At HeartFlow, we recognize the profound impact that slavery, in all its forms, has had throughout history and continues to have in various parts of the world today. We acknowledge the deep and lasting harm caused by the transatlantic slave trade, forced labor, and other systems of exploitation that have deprived millions of people of their fundamental rights, dignity, and freedom.
We are committed to understanding, addressing, and taking responsibility for any historical connections our organization may have had with slavery, whether directly or indirectly. It is our moral obligation to confront this legacy, promote education about slavery’s ongoing effects, and contribute to the fight against modern forms of slavery, including human trafficking, forced labor, and exploitation.
In line with this commitment, we strive to uphold the following principles:
This statement is not just a reflection on the past but a commitment to a more just and equitable future. We believe by addressing the legacy of slavery, we can contribute to building a society where freedom, justice, and dignity are truly available to all.
Modern slavery is the illegal exploitation of people for personal or commercial gain. It takes various forms, such as slavery, servitude, forced and compulsory labour, debt bondage and human trafficking, often in horrendous conditions from which the victim cannot escape. All of which have in common the deprivation of a person’s liberty by another in order to exploit them for personal or commercial gain.
Businesses have a key part to play in the effort to tackle this crime and protect vulnerable workers from exploitation. Heartflow have a zero tolerance approach to modern slavery. We are committed to acting ethically and with integrity in all our business dealings and relationships, and to implementing and enforcing effective systems and controls to ensure modern slavery is not taking place anywhere in our own business or our supply chains.
Section 54 of the UK Modern Slavery Act (2015) requires commercial organisations that operate in the UK and have an annual turnover above £36m to produce a Slavery and Human Trafficking statement each year.
We do not have an annual turnover above £36m, so therefore are not required under this legislation to produce a yearly statement. However, we choose to voluntarily produce a statement.
The Modern Slavery Act specifically states that any statement must include ‘the steps the organisation has taken during the financial year to ensure that slavery and human trafficking is not taking place in any of its supply chains, and in any part of its own business’
We cannot guarantee that the entire supply chain is slavery free, and this is not a requirement, but we will demonstrate the steps we have taken to assess risk and mitigate those.
HeartFlow is a medical technology company revolutionizing precision heart care globally. HeartFlow’s non-invasive personalized cardiac test provides unprecedented visualization of each patient’s coronary arteries, enabling physicians to create more effective treatment plans for their patients.
Heartflow is committed to ensuring transparency in our own business and our supply chains and expect the same due diligence and commitment from our suppliers, contractors and business partners.
When procuring goods or services we have processes in place to carry out third party due diligence.
This includes:
Process improvements currently in process include:
Our suppliers are risk assessed in terms of Quality, Information Security, and Privacy
Heartflow has an approved supplier list of around 190 suppliers. A desktop audit of these suppliers is conducted annually using the following methodology:
The nature of the organisational structure means that the risk within the business and supply chain for Tier 1 is identified as overall low.
7.7% of our overall supplier list fall into medium risk categories.
Further audit and due diligence is planned in the next financial year with the medium and high risk suppliers the first priority.
This risk level will be reviewed yearly and reported on.
We have not mapped our supply chain in tier 2 at this time. This is an area of improvement that is under management and the Procurement Committee’s review.
We will use key performance indicators (KPIs) to measure how effective our actions are to identify and address modern slavery practices in any part of our operations and supply chains moving forward in 2025.
Below are the key performance areas that we assess:
Against each of these focus areas we have developed KPIs that are used to assess the effectiveness of our actions. These include:
Over subsequent reporting periods, we will continue to review and enhance these KPIs and develop further metrics to assess the effectiveness of our actions, in line with continuous improvement. This will be captured and logged within our Management Reviews.
We provide third party independent training on Modern Slavery through ‘Tick the Box Compliance Solutions’ to all employees.
The training will cover:
The training will be delivered through HeartFLow’s Learning Management System and participants are required to pass the course using a competency-based exam that is built into the course.
The training is mandatory and is provided at hire and annually thereafter.
If a case of Modern Slavery is suspected, then the following is advised. A suspected victim of modern slavery is not to be confronted directly as this may endanger them.
If there is an immediate risk to life, then call a local emergency number (e.g. 911 in the US, 112 in Europe, 999 in the UK).
If wider – If there is no immediate risk to life, then contact the national helpline or report it online as listed below.
Country | Helpline | Phone | On-line |
---|---|---|---|
EU | Anti-trafficking hotline | See https://www.europeanfreedomnetwork.org/hotline/ | |
UK | Modern Slavery Helpline | 08000 232 700 https://www.modernslaveryhelpline.org/report | |
US | National Human Trafficking Hotline | 1-888-373-7888 https://humantraffickinghotline.org/en/report-trafficking |
Employees are required to take their suspicions to their direct manager.
If there are concerns around modern slavery with any of our suppliers we will first look to work with them to remedy the situation with an improvement action plan implemented and more rigorous auditing of the organization.
If the response from any of our suppliers, here in the UK or abroad, seems inadequate and appropriate measures are not put in place to address coercion, threat, abuse, and exploitation of workers, then we would look to give that company more support, guidance and incentives to tackle the issue. This could include working with at-risk suppliers to provide training, messages and business incentives or guidance to implement anti-slavery policies.
If modern slavery is identified or suspected abroad, and resolution is not possible with the supplier, then we will engage with local Non-Governmental Organisations, industry bodies, trade unions or other support organisations to attempt to remedy the situation. If warranted, we will contact local government and law enforcement bodies. Our approach will always consider the safest outcome for the potential victims while also remembering the economic influence and control which the organisation holds over those who may be committing these crimes.
If, after receiving support, the supplier is not taking the issue seriously, and it remains unresolved, then we will reconsider our commercial relationship with that supplier. These actions would then be included in the next statement produced.
Any employee who breaches this statement will face disciplinary action, which could result in dismissal for misconduct or gross misconduct.
Any suppliers, individuals or organisations working with us, or on our behalf who breach this policy may have their relationship or contract with us terminated.
HeartFlow staff with responsibility for this statement:
This statement will be reviewed by senior management, signed by a director or equivalent and then published on our website, and also uploaded to the following register: https://modern-slavery-statement-registry.service.gov.uk
Internally it will be sent to all employees and sent to our supply chain and other interested stakeholders.
SIGNED:
NAME: Francesco Jatta
JOB TITLE: EMEA Sales & Marketing VP
DATE: 12/6/2024 | 1:27 PM PST
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.